Drugs / ARGININE
ARGININE
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | LysaKare | — | 2019-07-25 | europa.eu ↗ |
Trials 47
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00848302 | Sep 2009 → Jan 2011 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT06182267 | Nov → Dec 2023 | dental caries | Colgate Palmolive | Completed | No outcome recorded |
| Phase 1 | NCT04800692 | Jun 2021 → Jul 2027 expected | intermittent vascular claudication, peripheral arterial disease | Louis Messina | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03679780 | Oct 2018 → Jul 2023 | cardiovascular disorder | The University of Texas at Arlington | Completed | No outcome recorded |
| Phase 1 | NCT01388764 | Jan → May 2012 | Becker muscular dystrophy, Duchenne muscular dystrophy, neuromuscular disease caused by qualitative or quantitative defects of dystrophin | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02516085 | Jan → Oct 2012 | Duchenne muscular dystrophy | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01485757 | Jul 2011 → Jul 2015 | — | University of Michigan | Terminated | No outcome recorded |
| Phase 1 | NCT00056433 | Mar 2003 → Dec 2006 | sickle cell disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00134433 | Nov 2004 → Mar 2007 | coronary artery disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 212 trials · 1 missed | ||||||
| Phase 2 | NCT06967428 | Sep 2025 → Jan 2026 overdue | — | Independent Medical Alliance | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05932979 | May → Nov 2023 | idiopathic bilateral vestibulopathy | Centro Universitario de Tonalá | Withdrawn | No outcome recorded |
| Phase 2 | NCT04535427 | Jan 2021 → Jan 2023 | rheumatoid arthritis | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04054973 | Sep 2019 → Dec 2021 | schizoaffective disorder, schizophrenia | University of Massachusetts, Worcester | Withdrawn | No outcome recorded |
| Phase 2 | NCT02838030 | Jul 2018 → Jul 2021 | — | University of Guadalajara | Suspended | No outcome recorded |
| Phase 2 | NCT03861416 | Mar 2018 → Sep 2019 | peripheral arterial disease | POLYSAN Scientific & Technological Pharmaceutical Company | Completed | No outcome recorded |
| Phase 2 | NCT02536170 | Feb 2016 → Feb 2021 | sickle cell disease | Emory University | Completed | Missed primary |
| Phase 2 | NCT01603446 | May 2012 → May 2013 | MELAS syndrome | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 2 | NCT01439555 | Nov 2011 → Nov 2017 | Alzheimer disease | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 2 | NCT01105130 | Oct 2010 → Feb 2014 | erectile dysfunction, prostate cancer, radiation-induced disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00405665 | Nov 2006 → Jun 2009 | cystic fibrosis | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 2 | NCT00001752 | Sep 1998 → Jul 2000 | hyperlipidemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05281562 | Feb → Mar 2023 | diabetes mellitus, diabetic neuropathy, ulcer of lower limbs | Prisma Health-Midlands | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT01263041 | May 2011 → Feb 2014 | infectious disease with sepsis, necrotizing enterocolitis | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT00137124 | May 2006 → Dec 2009 | essential hypertension | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 310 trials · 2 missed | ||||||
| Phase 3 | NCT06405243 | Jun → Dec 2024 | polycystic ovary syndrome | Beni-Suef University | Unknown | No outcome recorded |
| Phase 3 | NCT04813471 | Jan → Mar 2021 | COVID-19 | Lebanese American University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT04631536 | Jan 2021 → Mar 2022 | COVID-19 | Lebanese American University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02291458 | Nov 2014 → Oct 2015 | glucose intolerance | Maastricht University Medical Center | Unknown | Missed primary |
| Phase 3 | NCT00571766 | Nov 2007 → Dec 2008 | hypertension, pregnancy-induced | University of Modena and Reggio Emilia | Completed | No outcome recorded |
| Phase 3 | NCT00974714 | Sep 2007 → Jun 2009 | hypertension, pregnancy-induced | University of Modena and Reggio Emilia | Completed | No outcome recorded |
| Phase 3 | NCT01142219 | Sep 2006 → Jan 2008 | sickle cell disease | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 3 | NCT00408577 | Nov 2004 → Nov 2006 | cardiovascular disorder | IRCCS San Raffaele | Completed | No outcome recorded |
| Phase 3 | NCT00157521 | Sep 2002 → May 2006 | preeclampsia | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 3 | NCT00549575 | Jul 2000 → Jun 2006 | fetal growth restriction | Nantes University Hospital | Terminated | Missed primary |
| Phase 46 trials | ||||||
| Phase 4 | NCT06947265 | Jan 2024 → Jan 2025 | erectile dysfunction | Fayoum University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05029778 | Oct 2021 | fetal growth restriction | Hospital Civil de Guadalajara | Unknown | No outcome recorded |
| Phase 4 | NCT03982160 | Feb 2018 → Dec 2026 expected | chronic kidney disease | The University of Texas at Arlington | Active not recruiting | No outcome recorded |
| Phase 4 | NCT00856817 | Mar 2009 → ? | atherosclerotic cardiovascular disease | Radboud University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00785811 | Oct → Dec 2008 | muscular atrophy | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00213915 | Feb → Dec 2004 | — | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| Phase not applicable7 trials · 1 missed | ||||||
| — | NCT06728644 | Jul 2024 → Jul 2025 | polycystic ovary syndrome | Shanghai 10th People's Hospital | Completed | No outcome recorded |
| — | NCT05653895 | Dec 2022 → Dec 2023 | polycystic ovary syndrome | Khyber Medical University Peshawar | Completed | No outcome recorded |
| — | NCT04701463 | Jan → Nov 2020 | obesity disorder, skin disorder | Azienda di Servizi alla Persona di Pavia | Completed | No outcome recorded |
| — | NCT03321292 | Oct 2017 → Dec 2018 | selective intrauterine growth restriction | Ain Shams University | Unknown | No outcome recorded |
| — | NCT00051376 | Sep 2001 → Aug 2006 | myocardial infarction | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
| — | NCT00284076 | Feb 2000 → Jul 2006 | peripheral vascular disease | Stanford University | Completed | No outcome recorded |
| — | NCT00275158 | Jan 2000 → Dec 2003 | preeclampsia | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Comparator or background therapy17 trials | ||||||
| Phase 2 | NCT07394270 Comparator | Feb 2026 → Mar 2027 expected | heart failure | German University in Cairo | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07135037 Comparator | Sep 2024 → Sep 2025 overdue | oligohydramnios | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 2 | NCT01841281 Comparator | Aug 2013 → Aug 2018 | asthma | Nicholas Kenyon | Completed | No outcome recorded |
| Phase 2 | NCT00280683 Comparator | Dec 2004 → Nov 2008 | asthma | University of California, Davis | Completed | No outcome recorded |
| Phase 3 | NCT06044194 Comparator | Mar 2023 → Sep 2024 | heart failure | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Unknown | No outcome recorded |
| Phase 3 | NCT05470998 Comparator | Jul 2022 → Oct 2024 | sickle cell disease | Tanta University | Completed | No outcome recorded |
| Phase 3 | NCT00677339 Comparator | Jun 2008 → Feb 2010 | pulmonary tuberculosis | Menzies School of Health Research | Completed | No outcome recorded |
| Phase 3 | NCT00917449 Comparator | Dec 2005 → Jun 2009 | glucose intolerance, metabolic syndrome X | IRCCS San Raffaele | Completed | No outcome recorded |
| Phase 4 | NCT06753526 Comparator | Jul 2023 → Apr 2024 | ureterolithiasis | Sohag University | Completed | No outcome recorded |
| Phase 4 | NCT04643600 Comparator | Mar 2019 → Feb 2022 | — | Goranka Radmilović | Unknown | No outcome recorded |
| Phase 4 | NCT03402191 Comparator | Jul 2016 → Dec 2023 | thalassemia | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT01038622 Comparator | Nov 2009 → Nov 2010 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT02117206 Comparator | Nov 2005 → Mar 2012 | limb ischemia, mitochondrial disease | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| Phase 4 | NCT00777075 Comparator | Jul 2003 → Nov 2005 | erectile dysfunction | Hannover Medical School | Completed | No outcome recorded |
| — | NCT03834610 Comparator | Oct 2017 → Oct 2018 | erectile dysfunction | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT00718510 Comparator | Sep 2009 → Jul 2011 | schizophrenia | University of Alberta | Completed | No outcome recorded |
| — | NCT00603720 Comparator | Sep 2005 → Jun 2008 | cardiovascular disorder | Washington University School of Medicine | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 69 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARGININE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1485 ↗ |
| Known as | Arginina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1485 ↗ |
| Known as | L ARG | “We ran a prospective pilot in 3 MELAS sibs (m.3243A>G tRNALeu(UUR)) with variable % mutant blood mtDNA to assess effects of L-Arginine (L-Arg) (single dose and 6-wk...” PMID 32881886 ↗ Sep 20202“Objective: To evaluate whether variants of the eNOS gene are associated with endothelial and metabolic responses to L-arginine (L-arg) supplementation.” PMID 26385052 ↗ Aug 2015 “Drug: L ARG” NCT00549575 ↗ |
| Known as | L-arginine | “L-Arginine is an amino acid that plays a role in a number of metabolic pathways and serves as a substrate for NOS (Nitric Oxide synthase) enzyme which is essentially involved...” NCT05653895 ↗70“This daily intervention over 3 months combines 4 g L-serine, 14 g L-glutamine, 3 g L-arginine, 2.5 g N-acetylcysteine, 5.75 g L-citrulline, 1 g vitamin C, and 5 g creatine to...” NCT06967428 ↗ “Pharmacokinetic (PK) study of L-arginine after exaggerated oral use of the novel dentifrice product COL101 after repeated daily applications in healthy adult subjects.” NCT06182267 ↗ “Patients were randomly assigned to receive L-arginine (goal dose of 3 g 3 times a day) or matching placebo for 6 months.” PMID 16391217 ↗ Jan 2006 “After double-blind randomization, patients received either 14 g/day of L-arginine, or a placebo.” PMID 19359073 ↗ Apr 2009 “Group (1) was given daily 3 g(three divided doses) oral tablets of L-arginine for eight weeks.” NCT06947265 ↗ “the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach” NCT04643600 ↗ “L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate” NCT04701463 ↗ “receive L-arginine 3g + l-Citruline 2 g PO, for 24 h, until birth.” NCT05029778 ↗ “L-arginine supplementation for the treatment of pre-eclampsia” NCT00275158 ↗ “L-arginine 3 gm sachets are used twice daily” NCT07394270 ↗ |
| Known as | L-arginine Veyron | “Drug: L-arginine (L-arginine Veyron)” NCT02117206 ↗ |
| Known as | NSC-206269 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1485 ↗ |
| Known as | Unifuzol | “the drug Unifuzol® (L-arginine)” NCT03861416 ↗ |
| Action | Activate | “aids in nitric oxide production” NCT00603720 ↗ |
| Modality | Small molecule | “An amino acid called L-arginine” NCT00134433 ↗ |
| Route | Oral | “oral administration of L-Arginine” NCT00051376 ↗ |